EMBO Molecular Medicine : Impact Factor & More
eISSN: 1757-4684pISSN: 1757-4676
Open AccessShare this on:
Key Metrics
CiteScore 
16.2
Eigenfactor
0.01 - 0.05
H-Index
130
Impact Factor
10 - 15
Scite Index
0.95 5-Year SI
SJR
Q1Molecular Medicine
SNIP
2.15
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on EMBO Molecular Medicine
EMBO Molecular Medicine Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 5000 | GBP 3960 | EUR 4500 |
| Publication Time | 26 |
| Editorial Review Process | Anonymous peer review,Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | EMBO |
| Frequency | Monthly |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review,Double anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in EMBO Molecular Medicine ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in EMBO Molecular Medicine
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer.
- 19 May 2026
- EMBO molecular medicine
Adipocytes influence choroidal neovascularization via PRDM16.
- 19 May 2026
- EMBO molecular medicine
Author Correction: Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins.
- 19 May 2026
- EMBO molecular medicine
Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.
- 15 May 2026
- EMBO molecular medicine
Targeted enzymatic therapy for coeliac disease.
- 14 May 2026
- EMBO molecular medicine
Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation.
- 14 May 2026
- EMBO molecular medicine
WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer.
- 19 May 2026
- EMBO molecular medicine
Adipocytes influence choroidal neovascularization via PRDM16.
- 19 May 2026
- EMBO molecular medicine
Author Correction: Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins.
- 19 May 2026
- EMBO molecular medicine
Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.
- 15 May 2026
- EMBO molecular medicine
Targeted enzymatic therapy for coeliac disease.
- 14 May 2026
- EMBO molecular medicine
Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation.
- 14 May 2026
- EMBO molecular medicine
FAQs on EMBO Molecular Medicine
How long has EMBO Molecular Medicine been actively publishing? 
What is the publishing frequency of EMBO Molecular Medicine?
How many articles did EMBO Molecular Medicine publish last year?
What is the eISSN & pISSN for EMBO Molecular Medicine?
What is Citescore for EMBO Molecular Medicine?
What is the H Index for EMBO Molecular Medicine ?
What is SNIP score for EMBO Molecular Medicine?
What is the SJR for EMBO Molecular Medicine?
Who is the publisher of EMBO Molecular Medicine?
